In particular, an increased risk for cardiac arrhythmia (Hennessy et al., 2002) as a result of their anti-dopaminergic activity and inhibition of hERG channels could impede repositioning of some of these PTH for the treatment of PCa due to potential concerns by regulatory agencies. This evidence concerns the gene PTH and cardiac arrhythmia.